Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Drug 1: LY3023414; Drug 2: Prexasertib · 1 trial · 1 indication
To assess the objective response rate associated with LY3023414 and prexasertib in metastatic TNBC patients. Objective response is measured as prolonged clinical benefit; clinical benefit is defined as progression free survival on study therapy for at least 6 months.
| Arm | Type | Description |
|---|---|---|
| LY3023414 + prexasertib | EXPERIMENTAL | Patients with metastatic TNBC who meet the enrollment criteria will receive LY3023414 and prexasertib until disease progression. Patients whose disease does not respond to the combination of LY3023414 and prexasertib may be treated with standard of care breast cancer therapies off study, at the recommendation of the treating physician. |
| Name | Type | Description |
|---|---|---|
| Drug 1: LY3023414; Drug 2: Prexasertib | COMBINATION_PRODUCT | Metastatic TNBC patients will consent to and undergo core needle biopsies of a metastatic lesion for NGS, RPPA, and other molecular analyses at study entry. Patients will then be treated with 150 mg LY3023414 PO BID and prexasertib 80 mg/m\^2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Any time after the completion of Cycle 2 of the treatment combination, or at the physician's discretion, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted. Treatment will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses. |
Inclusion Criteria: 1. Patients ≥18 years of age. Patients must agree to use one highly effective (less than 1% failure rate) method of contraception or use a combination of two effective methods of contraception during treatment with study drug and for at least 12 weeks following the last dose of ...
LY3023414 is an investigational small molecule being studied in combination with prexasertib for the treatment of metastatic triple-negative breast cancer. It was evaluated in a Phase 2 clinical trial in the United States. The drug is not approved and remains in clinical development.
LY3023414 is a small molecule developed by Eli Lilly and Company. Its molecular target has not been disclosed in the available information. It is being investigated in combination with prexasertib for metastatic triple-negative breast cancer.
LY3023414 is developed by Eli Lilly and Company, traded on the New York Stock Exchange under the ticker LLY. The company is investigating the drug in combination with prexasertib for the treatment of metastatic triple-negative breast cancer.
LY3023414 is in Phase 2 clinical development. It was studied in a completed Phase 2 trial for metastatic triple-negative breast cancer. The drug is investigational and has not been approved by regulatory authorities.
LY3023414 was evaluated in clinical trial NCT04032080, titled "LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer." This Phase 2 study enrolled 10 participants in the United States and has been completed.
No, LY3023414 is not the same as prexasertib. They are two distinct investigational drugs developed by Eli Lilly and Company. In clinical trial NCT04032080, they were studied in combination for the treatment of metastatic triple-negative breast cancer.